ArticleNeurology2021

Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials.

Joshua D Grill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.